Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN50580483
ISRCTN50580483
Completed
Phase 3

A randomised controlled phase III trial of patients with non-metastatic Ewing sarcoma treated with either a prolonged treatment or a shorter dose-intense treatment and the effect on probability of survival

Italian Sarcoma Group (Italy)0 sites220 target enrollmentApril 22, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Italian Sarcoma Group (Italy)
Enrollment
220
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 22, 2010
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Italian Sarcoma Group (Italy)

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients with non\-metastatic Ewing sarcoma
  • •2\. Aged less than 41 years, either sex
  • •3\. No previous treatment for the disease
  • •4\. Informed consent

Exclusion Criteria

  • •1\. Metastatic Ewing sarcoma
  • •2\. Medical contraindications to the protocol drugs

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
A Phase III randomized controlled clinical trial of CARBOPLATIN and PACLITAXEL(OR GEMCITABINE) alone or in combination with BEVACIZUMAB (NSC #704865, IND #7921) followed by BEVACIZUMAB and secondary cytoredutive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer.PLATINUM-SENSITIVE, RECURRENT OVARIAN, PERITONEAL PRIMARY AND FALLOPIAN TUBE CANCER
JPRN-UMIN000003682Gynecologic Oncology Group1,050
Recruiting
Phase 3
Phase III randomised trial evaluating chemotherapy early treatment intensification with temozolomide in adults present with a glioblastoma
2022-500451-23-00Centre Oscar Lambret400
Active, not recruiting
Not Applicable
Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic non-small-cell lung cnacer patients.Treatment in locally advanced or metastatic non-small-lung cancer.
EUCTR2004-001904-10-EEPierre Fabre Medicament represented by IRPF350
Active, not recruiting
Not Applicable
Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic non-small-cell lung cnacer patients.
EUCTR2004-001904-10-ATPierre Fabre Médicament represented by IRPF350
Active, not recruiting
Phase 1
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-005731-41-IEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990